Open-label, Randomized Controlled Trial Comparing Tocilizumab to Anti-TNF Treatment and Discovery of Biomarkers for Treatment Selection in Rheumatoid Arthritis Patients With Inadequate Response to a First Anti-TNF
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Tocilizumab (Primary) ; Tocilizumab (Primary) ; Adalimumab; Certolizumab pegol; Etanercept; Golimumab; Infliximab
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms RAFTING
- 03 Oct 2017 Planned initiation date changed from 15 Sep 2017 to 1 Nov 2017.
- 27 Jul 2017 Planned End Date changed from 1 Jun 2021 to 1 Sep 2021.
- 27 Jul 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Sep 2018.